echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The safety, pharmacokinetics and pharmacodynamics of the cancer drug candidate E-602 invented by Nobel laureates in non-human primates

    The safety, pharmacokinetics and pharmacodynamics of the cancer drug candidate E-602 invented by Nobel laureates in non-human primates

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Sialic acid is a special glycan that can be recognized by a range of surface proteins that are found primarily on innate immune cells but also on activated T cells at


    E-602 is a new, first-class engineered human sialidase (Neu2)Fc fusion developed for cancer treatment


    Developed by Palleon, an innovative drug company founded by 2022 Nobel Laureate in Chemistry Carolyn Bertozzi, E-602 will provide data


    To support clinical development, we conducted a good laboratory-practice, one-month repeated dosing toxicity study evaluating the pharmacokinetics (PK) parameters, pharmacodynamic (PD) effects, and safety profiles of E-602 in crab-eating monkeys by weekly intravenous infusion of E-602 for a total of five doses


    Despite the short half-life of E-602, the PD effect of desialylation of immune cells persists on T cells for up to 7 days, consistent with the enzymatic mechanism of action of E-602


    At present, palleon has reached a strategic cooperation with Henlius Fuhong to jointly develop two bifunctional antibodies, sialidase fusion proteins, for the treatment of a variety of cancers


    Original Source:

    Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.